Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: A LYSA/SFGM-TC study-Reference-Cited by-同舟云学术

Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: A LYSA/SFGM-TC study

Published:2017-09 Issue: Volume:83 Page:146-153
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Morel Alexandre,Brière Josette,Lamant Laurence,Loschi Michaël,Haioun Corinne,Delarue Richard,Tournilhac Olivier,Bachy Emmanuel,Sonet Anne,Amorim Sandy,Laurent Camille,Gaulard Philippe,Tilly Hervé,Sibon David

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference21 articles.

1. The 2016 revision of the World Health Organization classification of lymphoid neoplasms;Swerdlow;Blood,2016

2. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials;Sibon;J Clin Oncol,2012

3. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project;Savage;Blood,2008

4. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group;Schmitz;Blood,2010

5. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry;Ellin;Blood,2014

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Programmed Death Ligand 1 (PD-L1) Expression in Lymphomas: State of the Art;International Journal of Molecular Sciences;2024-06-11

2. Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trial;European Journal of Cancer;2023-09

3. Effect of arsenic trioxide plus etoposide, solumedrol, high‑dose cytarabine and cisplatin chemotherapy on the treatment of relapsed or ref7ractory ALK+ anaplastic large cell lymphoma;Oncology Letters;2023-05-04

4. ALK-negative anaplastic large cell lymphoma with DUSP22 rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA study;Haematologica;2022-12-01

5. Peripheral T-Cell Lymphomas: Therapeutic Approaches;Cancers;2022-05-08